About John Orwin
John Orwin is a director at First Tracks Biotherapeutics.
Form D filings name John Orwin as a director at CARGO Therapeutics.
John Orwin reports to the SEC as a director or officer of 10 public companies, including Anaptysbio (ANAB), Travere Therapeutics (TVTX) and CARGO Therapeutics (CRGX).
John Orwin first appears on SEC filings in 2009.
Experience
This experience comes from SEC filings. The years are when the filings name John Orwin in the role, so the role may have started earlier or lasted longer.
FI
First Tracks Biotherapeutics, Inc.
Director
2026 · Public company (TRAX)
AI
Anaptysbio, Inc.
Director
2023 – 2026 · Public company (ANAB)
TI
Travere Therapeutics, Inc.
Director
2017 – 2026 · Public company (TVTX)
AI
Atreca, Inc.
President & CEO, director
2019 – 2024 · Public company (BCEL)
SI
Seagen Inc.
Director
2014 – 2023 · Public company (SGEN)
AI
Array Biopharma Inc.
Director
2012 – 2019 · Public company (ARRY)
RI
Relypsa Inc
President & CEO, director
2013 – 2016 · Public company (RLYP)
AI
Affymax Inc.
CEO and director
2010 – 2013 · Public company (AFFY)
NI
NeurogesX Inc
Director
2009 – 2012 · Public company (NGSX)
Key Colleagues at Startups
The people John Orwin works with at each company, as listed on that company's latest Form D.
CARGO Therapeutics, Inc. · Form D, Mar 1, 2023
GC
Gina Chapman
Chief Executive Officer and director
AB
Abraham Bassan
Director
CL
Cassandra Gianna Luca
Director
JW
Jeffrey Walsh
Director
KV
Krishnan Viswanadhan
Director
CM
Crystal Mackall
Director
HL
Heath Lukatch
Director
AR
Anup Radhakrishnan
Executive officer